论文部分内容阅读
为了解抗HBcIgE在原发性肝癌患者中的颇率,我们对97例肝癌病人、46例无症状HBsAg携带者、43例慢性迁延型肝炎、38例慢性活动型肝炎进行对照研究,结果表明:肝癌病人抗HBcIgE阳性60例(61.9%)、其它各组分别为20例(43.5%)、18例(41.9%)和19例(50.0%)。60例抗HBcIgE阳性的肝癌病人中的HBeAg的阳性率也最高(P<0.05)。结果提示抗HBcIgE检测在肝癌的发病中有一定价值。
In order to understand the anti-HBcIgE rate in patients with primary liver cancer, 97 cases of liver cancer patients, 46 cases of asymptomatic HBsAg carriers, 43 cases of chronic persistent hepatitis, 38 cases of chronic active hepatitis control study, the results showed that: Sixteen patients (61.9%) were positive for anti-HBcIgE from liver cancer patients, 20 (43.5%), 18 (41.9%) and 19 (50.0%) patients in other groups. The positive rate of HBeAg in 60 patients with anti-HBcIgE-positive liver cancer was also the highest (P <0.05). The results suggest that anti-HBcIgE detection in the pathogenesis of liver cancer has a certain value.